A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

Elias Jabbour, Hagop Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Zeev Estrov, Srdan Verstovsek, Susan O'Brien, Stefan Faderl, Deborah A. Thomas, John J. Wright, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences